News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Verto, a Subsidiary of Hadasit Ltd. Bio-Holdings, Completes Successful Human Clinical Trial of a Treatment for Lupus


7/21/2008 10:07:23 AM

JERUSALEM--(BUSINESS WIRE)--Hadasit Bio-Holdings, (HBL) a subsidiary of Hadasit (the technology transfer company of the Hadassah - Hebrew University Medical Center), which is traded on the Tel Aviv Stock Exchange under the symbol HDST, announced today that one of its portfolio companies, Verto (in which it has a 75% stake), has successfully completed a human clinical trial of a device for treating patients who suffer from systemic lupus erythematosus.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES